Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Replimune Group (NASDAQ: REPL) announced two key presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) in Houston, Texas. The first is a late-breaking oral presentation featuring primary analysis data from the IGNYTE clinical trial, including subgroup and initial biomarker analyses of RP1 plus nivolumab in anti-PD1 failed melanoma patients. Dr. Michael K. Wong from MD Anderson Cancer Center will present this on November 9, 2024.
Additionally, Dr. Diwakar Davar from UPMC Hillman Cancer Center will present an encore poster on November 8, 2024, sharing data from the ARTACUS clinical trial, which studied RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies.
Replimune Group (NASDAQ: REPL) ha annunciato due presentazioni chiave al 39° Congresso Annuale della Society for Immunotherapy of Cancer (SITC 2024) a Houston, Texas. La prima è una presentazione orale di grande rilevanza che presenta i dati di analisi primaria del trial clinico IGNITE, compresi analisi di sottogruppi e biomarcatori iniziali di RP1 più nivolumab in pazienti con melanoma che hanno fallito il trattamento anti-PD1. Il Dr. Michael K. Wong del MD Anderson Cancer Center presenterà questo il 9 novembre 2024.
Inoltre, il Dr. Diwakar Davar dell'UPMC Hillman Cancer Center presenterà un poster di ripetizione l'8 novembre 2024, condividendo dati dal trial clinico ARTACUS, che ha studiato la monoterapia con RP1 in pazienti trapiantati di organi solidi con neoplasie cutanee avanzate.
Replimune Group (NASDAQ: REPL) anunció dos presentaciones clave en el 39º Congreso Anual de la Society for Immunotherapy of Cancer (SITC 2024) en Houston, Texas. La primera es una presentación oral de última hora que presenta datos del análisis primario del ensayo clínico IGNITE, incluidos análisis de subgrupos y biomarcadores iniciales de RP1 más nivolumab en pacientes con melanoma que fallaron en el tratamiento anti-PD1. El Dr. Michael K. Wong del MD Anderson Cancer Center presentará esto el 9 de noviembre de 2024.
Adicionalmente, el Dr. Diwakar Davar del UPMC Hillman Cancer Center presentará un poster adicional el 8 de noviembre de 2024, compartiendo datos del ensayo clínico ARTACUS, que estudió la monoterapia con RP1 en pacientes trasplantados de órganos sólidos con malignidades cutáneas avanzadas.
Replimune Group (NASDAQ: REPL)는 텍사스 휴스턴에서 열리는 제39차 미국 암 면역치료학회(SITC 2024)에서 두 가지 주요 발표를 했습니다. 첫 번째 발표는 IGNYTE 임상 시험의 주요 분석 데이터를 포함하는 긴급 구두 발표로, RP1과 니볼루맙의 조합이 PD-1 치료에 실패한 멜라노마 환자 그룹 및 초기 바이오마커 분석을 특징으로 합니다. MD Anderson Cancer Center의 Michael K. Wong 박사가 2024년 11월 9일에 발표할 예정입니다.
또한, UPMC Hillman Cancer Center의 Diwakar Davar 박사가 2024년 11월 8일에 추가 포스터 발표를 통해 RP1 단독 요법이 고급 피부 악성종양을 가진 장기 이식 환자에서 어떻게 연구되었는지를 공유할 것입니다. 이 발표는 ARTACUS 임상 시험의 데이터를 포함합니다.
Replimune Group (NASDAQ: REPL) a annoncé deux présentations clés lors du 39ème Congrès Annuel de la Society for Immunotherapy of Cancer (SITC 2024) à Houston, Texas. La première est une présentation orale à fort impact présentant les données d'analyse primaire de l', y compris des analyses de sous-groupes et des biomarqueurs initiaux de RP1 plus nivolumab chez des patients atteints de mélanome ayant échoué au traitement anti-PD1. Le Dr. Michael K. Wong du MD Anderson Cancer Center présentera cela le 9 novembre 2024.
De plus, le Dr. Diwakar Davar du UPMC Hillman Cancer Center présentera un poster complémentaire le 8 novembre 2024, partageant des données de l', qui a étudié la monothérapie RP1 chez des patients ayant bénéficié d'une transplantation d'organes solides avec des malignités cutanées avancées.
Replimune Group (NASDAQ: REPL) gab zwei wichtige Präsentationen auf dem 39. Jahresmeeting der Society for Immunotherapy of Cancer (SITC 2024) in Houston, Texas, bekannt. Die erste ist eine kurzfristige mündliche Präsentation, die primäre Analysedaten aus der IGNYTE-Studie enthält, einschließlich Untergruppen- und ersten Biomarkeranalysen von RP1 plus Nivolumab bei Patienten mit Melanom, die auf anti-PD1 nicht angesprochen haben. Dr. Michael K. Wong vom MD Anderson Cancer Center wird dies am 9. November 2024 präsentieren.
Zusätzlich wird Dr. Diwakar Davar vom UPMC Hillman Cancer Center am 8. November 2024 ein zusätzliches Poster präsentieren, das Daten aus der ARTACUS-Studie teilt, die RP1-Monotherapie bei Patienten mit soliden Organtransplantationen und fortgeschrittenen kutanen Malignitäten untersucht hat.
- None.
- None.
Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation
Data from ARTACUS clinical trial of RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies selected for encore poster presentation
WOBURN, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that a late-breaking abstract featuring the IGNYTE clinical trial primary analysis has been selected for oral presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) being held November 6-10, 2024, in Houston, Texas. Data from the ARTACUS clinical trial of RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies will also be shared in an encore poster presentation.
Presentation Details
Title: Primary analysis of the registration-intended cohort of patients with anti-PD1 failed melanoma from the IGNYTE trial of RP1 plus nivolumab, including clinical subgroup and initial biomarker data
Abstract Number: 1504
Presentation Session Title: Session 204 – Clinical Late-Breaking Abstract Session
Date and Time: Saturday, November 9, 2024, 11:45 am – 12:45 pm CST
Presenter: Michael K. Wong, MD, PhD, University of Texas MD Anderson Cancer Center
Title: Safety and efficacy results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)
Abstract Number: 693
Date and Time: Friday, November 8, 2024
Presenter: Diwakar Davar, MD, UPMC Hillman Cancer Center
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Forward Looking Statements
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the design and advancement of our clinical trials, the timing and sufficiency of our clinical trial outcomes to support potential approval of any of our product candidates, our goals to develop and commercialize our product candidates, patient enrollments in our existing and planned clinical trials and the timing thereof, and other statements identified by words such as “could,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, the availability of combination therapies needed to conduct our clinical trials, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus as a global pandemic and related public health issues and the Russian-Ukrainian and Israel-Hamas political and military conflicts, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
When will Replimune (REPL) present the IGNYTE trial results at SITC 2024?
What are the two clinical trials Replimune (REPL) is presenting at SITC 2024?